Lynch Biologics LLC

Lynch Biologics LLC is a Geistlich North America company specializing in oral and dental regenerative biologics for bone and soft tissue defects. The company's flagship product is GEM 21S®, a synthetic bone graft composed of purified, sterile recombinant human platelet-derived growth factor (rhPDGF-BB) combined with β-tricalcium phosphate. GEM 21S® is FDA-cleared and the first off-the-shelf source of purified rhPDGF approved for bone and soft tissue regeneration in oral surgery and periodontal applications. The product works by signaling and recruiting cells needed for bone and tissue regeneration (chemotaxis), promoting cellular proliferation and angiogenesis to support faster healing and new bone formation. The product is supported by extensive clinical evidence: over 500 publications, 60+ clinical studies, analysis of 1,650 defects, and application in approximately 5 million patients. Lynch Biologics serves dental surgeons, periodontists, and oral surgeons in regenerative dentistry and periodontal treatment. The company provides clinical education, webinar access, coding support, and case-based learning resources to support clinician adoption of growth factor biologics in clinical workflows.